Clinical Efficacy of Arbidol in Patients with 2019 Novel Coronavirus-Infected Pneumonia: A Retrospective Cohort Study

Xu, Kaijin; Chen, Yanfei; Yuan, Jing; Yi, Ping; Ding, Cheng; Wu, Wenrui; Li, Yongtao; Ni, Qin; Zhou, Rongrong; Li, Xiaohe; Xu, Min; Zhang, Ying; Zhao, Hong; Zhang, Xuan; Yu, Liang; Su, Junwei; Lang, Guanjing; Li, Jun; Wu, Xiaoxin; Guo, Yongzheng; Tao, Jingjing; Shi, Ding; Yu, Ling; Cao, Qing; Ruan, Bing; Liu, Lei; Wang, Zhaoqin; Xu, Yan; Liu, Yingxia; Sheng, Jifang; Li, Lanjuan

doi:10.2139/ssrn.3542148

Cited by 28 publications

(38 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It acts against influenza A and B by inhibiting viral fusion with cellular membrane and blocking the virus entry into host cells [23]. In a retrospective cohort study, arbidol accelerated the clearance of viral RNA in patients with COVID-19 compared to empirical treatment [14]. In China, it has been recommended as one of the antiviral drugs for COVID-19 [11].…”

Section: Discussionmentioning

confidence: 99%

“…The use of antiviral drugs approved for other conditions is largely empirical in these patients. Some antiviral drugs, such as chloroquine, arbidol, and lopinavir/ritonavir, have been investigated in small-scale studies and are recommended as options of antiviral regimens in China and some countries [11,[13][14][15][16][17]. However, the efficacy of these antiviral drugs on the SARS-CoV-2 RNA clearance remains largely unknown.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Associations of clinical characteristics and antiviral drugs with viral RNA clearance in patients with COVID-19 in Guangzhou, China: a retrospective cohort study

Chen

Zhang

Zhu

et al. 2020

Preprint

View full text Add to dashboard Cite

Background:The novel coronavirus disease 2019 characterized by respiratory symptoms has become a global pandemic although factors influencing viral RNA clearance remained unclear to inform optimal isolation period and treatment strategies. Methods:In this retrospective study, we included patients with confirmed COVID-19The associations of clinical characteristics and treatment regimens on time to viral RNA clearance were analyzed. Results:We examined 284 consecutive COVID-19 cases, accounting for 82% of confirmed cases in Guangzhou during this period. At the time of reporting (20 th March 2020), 276 (97.2%) had recovered and were discharged from hospital with a median hospital stay of 18 days (interquartile range [IQR]:13-24). Overall, 280 patients achieved viral RNA clearance with a median length of 12 days (IQR: 8-16) after onset of illness. Amongst them, 66.1% had viral RNA cleared within 14 days, and 89.3% within 21 days. Older age, severity of disease, time lag from illness onset to hospital admission, high body temperature, and corticosteroid use were associated with delayed clearance of viral RNA. None of the antiviral regimens (chloroquine, oseltamivir, arbidol, and lopinavir/ritonavir) improved viral RNA clearance.The use of lopinavir/ritonavir was associated with delayed clearance of viral RNA after adjusting for confounders. Conclusion:In patients with COVID-19, isolation for a minimum of 21 days after onset of illness may be warranted, while the use of antiviral drugs does not enhance viral RNA clearance.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Associations of clinical characteristics and antiviral drugs with viral RNA clearance in patients with COVID-19 in Guangzhou, China: a retrospective cohort study

Chen

Zhang

Zhu

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…One cohort study [58] involved 49 in the umifenovir plus conventional therapy group and 62 in the conventional therapy group (defined as treatment based on clinician's experiences and judgements). Results showed that umifenovir could accelerate and enhance the process of virus clearance (59.2% vs. 40.3%, P = 0.048), improve the local absorption of lung lesions (55.1% vs. 32.2%, P = 0.02), and reduce the demand of high flow nasal catheterization oxygen (P = 0.002).…”

Section: Implementation Considerationsmentioning

confidence: 99%

Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline (updated version)

et al. 2020

View full text Add to dashboard Cite

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of a rapidly spreading illness, coronavirus disease 2019 (COVID-19), affecting more than seventeen million people around the world. Diagnosis and treatment guidelines for clinicians caring for patients are needed. In the early stage, we have issued "A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)"; now there are many direct evidences emerged and may change some of previous recommendations and it is ripe for develop an evidence-based guideline. We formed a working group of clinical experts and methodologists. The steering group members proposed 29 questions that are relevant to the

show abstract

“…The innate pathogenesis of the virus leads to mild symptoms in which antiviral therapy can quickly improve the primary symptoms. Then, increased cytokines in the lungs and bone marrow lead to worsening of symptoms of in uenza virus or SARS-CoV infections (16,(23)(24)(25). Previous data have shown that there are two potential mechanisms involved in the process of lung damage caused by in uenza virus, including viral pathogenesis and the host's innate immune responses to the disease (26).…”

Section: Discussionmentioning

confidence: 99%

“…In vitro studies have shown that pro-in ammatory cytokines such as TNF-α, IL-8, and IL-6 decreased after treatment with Arbidol (8). Acute respiratory distress syndrome (ARDS) caused by increased response to in ammatory cytokines/chemokine has also been shown to be one of the main mechanisms of SARS-CoV and MERS-CoV infections (16,27). It seems that the effects of Arbidol should be re ected in the secondary symptoms of the disease.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Arbidol in Treatment of Patients with COVID-19 Infection: A Randomized Clinical Trial

Ghaderkhani

Khaneshan

Salami

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The outbreak of 2019-novel coronavirus has led to a high demand for finding effective antiviral agents. Preliminary experiments showed that Arbidol could inhibit coronavirus replication in vivo. There is limited data on the clinical efficacy of 2019-novel coronavirus-infected pneumonia (NCP). Therefore, we aimed to evaluate this medication based on clinical and laboratory results.Methods: The present study was designed as a clinical trial to investigate the advantages and disadvantages of this medicine compared to empirical treatment. For this purpose, multi-stage sampling was considered. 56 people were selected by accidental non-random sampling method. This sample size was subsequently divided into two groups by randomized block sampling (1:1). During the study, three patients left the case group. Their clinical symptoms were examined while taking these medicines in the disease course. The SPSS software was used for data analysis and the significance level was considered to be P<0.05.Results: On the seventh day, there were statistically significant differences in dry cough(p = 0.001), weakness(p = 0.004), gastrointestinal symptoms(p = 0.043) and shortness of breath (p = 0.001) between the two groups, and the Arbidol group had a faster recovery. During the disease course, there were statistically significant differences in Myalgia(p = 0.03), gastrointestinal symptoms(p = 0.047), and weakness(p = 0.007) were significantly different between the two groups.Conclusion: Symptoms improved faster in patients with mild to moderate disease who received Arbidol in their treatment regimen. In other words, adding Arbidol to the empirical treatment accelerated the recovery process of patients’ clinical symptoms.Registration: IR.TUMS.VCR.REC.1399.204, 04.13.2020 , http://ethics.research.ac.ir/IR.TUMS.VCR.REC.1399.204

show abstract

Clinical Efficacy of Arbidol in Patients with 2019 Novel Coronavirus-Infected Pneumonia: A Retrospective Cohort Study

Cited by 28 publications

References 0 publications

Associations of clinical characteristics and antiviral drugs with viral RNA clearance in patients with COVID-19 in Guangzhou, China: a retrospective cohort study

Associations of clinical characteristics and antiviral drugs with viral RNA clearance in patients with COVID-19 in Guangzhou, China: a retrospective cohort study

Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline (updated version)

Efficacy and Safety of Arbidol in Treatment of Patients with COVID-19 Infection: A Randomized Clinical Trial

Contact Info

Product

Resources

About